Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

Younes, Anas, Dr ; Berdeja, Jesus G, MD ; Patel, Manish R, MD ; Flinn, Ian, MD ; Gerecitano, John F, MD ; Neelapu, Sattva S, MD ; Kelly, Kevin R, MD ; Copeland, Amanda R, MSN ; Akins, Amy, BSN ; Clancy, Myles S, MBA ; Gong, Lucy, PharmD ; Wang, Jing, PhD ; Ma, Anna, MS ; Viner, Jaye L, MD ; Oki, Yasuhiro, MD

The lancet oncology, 2016-05, Vol.17 (5), p.622-631 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível